预约演示
更新于：2026-09-15
Lidocaine/Prilocaine
复方利多卡因
更新于：2026-09-15
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H42N4O2 |
InChIKeyWZSPWMATVLBWRS-UHFFFAOYSA-N |
CAS号101362-25-8 |
关联
303
项与 复方利多卡因 相关的临床试验CTRI/2025/09/095420
Optimizing Palatal Anesthesia in Children: EMLA Cream with Different Drug Delivery Systems
NCT07778043
Lidocaine-prilocaine Cream as Analgesia for In-office Levator Muscle Trigger Point Injections: a Pilot Randomized, Double-blinded, Placebo-controlled Trial
NCT07768059
A Double-blind Placebo-controlled Randomized Controlled Trial (RCT) of Self-application of Lidocaine 2.5%/Prilocaine 2.5% Cream for Intrauterine Device (IUD) Insertion and Endometrial Biopsy
100 项与 复方利多卡因 相关的临床结果
登录后查看更多信息
100 项与 复方利多卡因 相关的转化医学
登录后查看更多信息
100 项与 复方利多卡因 相关的专利（医药）
登录后查看更多信息
1,000
项与 复方利多卡因 相关的文献（医药）2026-07-01Minerva Anestesiologica
Chronic pain after mastectomy: current knowledge and knowledge gaps
Review
作者: Khan, Savera ; Payne, Cathryn ; Palmquist, Emily ; Curatolo, Michele ; Chiu, Abby P
Post-mastectomy pain syndrome (PMPS) is a frequent and burdensome complication of breast cancer surgery, manifesting as persistent pain following mastectomy, typically with neuropathic characteristics. This review synthesizes current knowledge on the epidemiology, prevention, and treatment of PMPS, and highlight knowledge gaps to inform future research. PMPS occurs in 28-52% of patients. It is associated with impairment in quality of life, and reductions in physical and psychosocial functioning. Consistently identified risk factors include younger age, extensive axillary surgery, total mastectomy, and preexisting chronic pain. Perioperative preventive strategies, such as topical EMLA cream, pregabalin, PECS II block, i.v. dexmedetomidine and flurbiprofen axetil, show potentially promising effects in reducing the incidence or severity of PMPS. Treatment options for established PMPS with potentially promising effects include topical capsaicin, amitriptyline, venlafaxine, multimodal pharmacological therapy, thermal radiofrequency of the stellate ganglion, and mindfulness-based cognitive therapy. For both preventive and therapeutic strategies, heterogeneity in study design, dosing regimens, and outcome frameworks, as well as the small sample size of most studies, limit the strength of evidence. Large knowledge gaps exist in the understanding of the molecular mechanisms associated with PMPS. Future research focusing on the molecular mechanisms promoting PMPS can facilitate the development of novel effective preventive and therapeutic strategies. Large-scale well-powered clinical trials on interventions aiming to prevent and treat PMPS are highly needed to inform evidence-based clinical practice. Future clinical studies should also aim to identify biomarkers that predict the efficacy of interventions in individual patients, thereby supporting personalized medicine.
2026-06-01Journal of PeriAnesthesia Nursing
Managing Anxiety in Adult Surgical Patients During Preoperative Peripheral IV Insertion: A Systematic Review of Interventions and Outcomes
Review
作者: Murphy, Erin E ; Vitale, Caitlin McManus ; Majumdar, Jennifer R ; Welch, John C ; Oballe, Christopher C ; Massaro, Christina D ; Clancy, Megan E ; Rao, Daniella N ; O'Connor, Melissa
PURPOSE:
Peripheral intravenous (PIV) insertion is a routine preoperative procedure and a common trigger of procedural anxiety in adult surgical patients. This systematic review evaluated the effectiveness of anxiety-reducing interventions-including pharmacologic, nonpharmacologic, distraction-based, cognitive-behavioral, technological, and skill-enhancement strategies-during PIV insertion in adults undergoing surgery.
DESIGN:
Systematic review conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and registered with International Prospective Register of Systematic Reviews (CRD42025648578).
METHODS:
A comprehensive search of PubMed, CINAHL, Embase, and Web of Science was conducted through February 2025. Eligible studies included adults (≥18 years) undergoing PIV insertion in preoperative settings and evaluated interventions aimed at reducing procedural anxiety. Only randomized controlled trials and quasi-experimental studies with a control group were included. Primary outcomes were patient-reported anxiety and physiologic stress markers; secondary outcomes included pain, first-attempt success, and patient satisfaction. Screening and data extraction were performed using Covidence.
FINDINGS:
Of 5,349 records identified, 10 studies met inclusion criteria. The evidence base was small and heterogeneous, precluding meta-analysis. Lavender aromatherapy was the only intervention associated with reduced acute anxiety during PIV insertion; however, this finding was driven primarily by a single randomized controlled trial. Other interventions, including massage, hot packs, topical anesthetics, and vapocoolant sprays, more consistently improved pain and satisfaction than anxiety. Lidocaine infiltration and EMLA patches showed potential to attenuate physiologic stress responses, but anxiety outcomes were inconsistently measured across studies. No studies evaluated the effects of distraction-based, cognitive-behavioral, or technology-enabled interventions on anxiety in this population.
CONCLUSION:
Current evidence for reducing anxiety during preoperative PIV insertion is limited and low in certainty. Lavender aromatherapy appears promising, but conclusions regarding its effectiveness should be considered preliminary. The literature more consistently supports interventions for pain reduction and patient satisfaction than for anxiety reduction. Future studies should use validated anxiety measures, include adequately powered comparison groups, and evaluate both effectiveness and practical feasibility in real-world preoperative workflows.
2026-05-01Journal of Pediatric Nursing-Nursing Care of Children & Families
Effects of 4% Lidocaine and EMLA in children undergoing venous procedures on vein caliber, pain, and child collaboration: Retrospective observational study
Article
作者: Magro, Gaia ; Vecellio, Lara ; Cogo, Paola ; Dussi, Gaia ; Palese, Alvisa ; Fabris, Stefano ; Cammarata, Giorgia ; Grassetti, Luca ; Cosattini, Sofia ; Clodig, Majda ; Semeraro, Asia
BACKGROUND:
Topical anesthetics such as 4% Lidocaine and Eutectic Mixture of Local Anesthetics (EMLA) are used for venipuncture and intravenous (IV) cannulation. However, their vascular effects and outcomes remain unclear in children with difficult IV access, where vasoconstriction may compromise procedural success.
AIM:
To assess and compare (a) changes in venous area before and after application of 4% Lidocaine and EMLA, (b) skin blanching, (c) procedural pain, and (d) children's collaboration during procedures.
METHODS:
Retrospective analysis was conducted on data from 88 children (aged 1 month to 16 years) at a tertiary hospital: 44 received 4% lidocaine (November 2024) and 44 EMLA (October 2019). Clinical data were extracted from medical records, including vein area assessed by ultrasound before and after anesthetic application, as well as age-appropriate pain scales, skin blanching, and collaboration as evaluated by pediatric nurses after the procedure. Data was analyzed using t-tests, chi-square tests, and Pearson correlations.
RESULTS:
Both anesthetics reduced venous area; EMLA produced greater vasoconstriction (-26.28% vs -3.27%, p = .002) and skin blanching (72.73% vs 25%, p < .001) than 4% Lidocaine. Pain was low in both groups (p = .07). Children who received EMLA showed higher collaboration (97.73% vs 75%, p < .001).
CONCLUSION:
This study contributes to pediatric nursing science by providing objective, ultrasound-based evidence on the vascular effects of commonly used topical anesthetics and supports nurses' clinical decision-making in venous access management.
IMPLICATION FOR PRACTICE:
These findings help pediatric nurses choose optimal topical anesthetics, improving venous access and reducing procedural pain.
100 项与 复方利多卡因 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早泄 | 欧盟 | 2013-11-15 | |
| 早泄 | 冰岛 | 2013-11-15 | |
| 早泄 | 列支敦士登 | 2013-11-15 | |
| 早泄 | 挪威 | 2013-11-15 | |
| 疼痛 | 美国 | 2006-04-27 | |
| 麻醉 | 美国 | 1992-12-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 22 | (2.5 g of Lidocaine 23% / Tetracaine 7% Ointment) | 壓淵壓選齋淵築齋網齋(構淵願積廠艱遞遞願顧) = 壓齋淵構獵繭築艱夢顧 醖蓋鹽齋膚願膚醖願壓 (鏇窪繭壓憲衊遞醖構簾, 1.90) 更多 | - | 2026-02-20 | ||
(7.5 g Lidocaine 2.5%/ Prilocaine 2.5% Cream) | 壓淵壓選齋淵築齋網齋(構淵願積廠艱遞遞願顧) = 鑰觸壓網繭遞鑰繭鏇窪 醖蓋鹽齋膚願膚醖願壓 (鏇窪繭壓憲衊遞醖構簾, 2.00) 更多 | ||||||
N/A | 72 | (Emla-cream) | 鹹廠淵構願衊繭蓋獵糧(憲鑰衊壓鏇醖網顧衊築) = 艱築簾艱餘鹽簾範醖壓 夢構範網顧襯鏇糧築製 (顧選顧窪顧願構積遞膚, 繭構夢糧襯鑰齋獵壓衊 ~ 構遞膚糧衊餘鏇製鹹醖) 更多 | - | 2025-10-23 | ||
Miniderm cream (Miniderm Cream) | 鹹廠淵構願衊繭蓋獵糧(憲鑰衊壓鏇醖網顧衊築) = 廠構壓獵鏇網簾鹽艱製 夢構範網顧襯鏇糧築製 (顧選顧窪顧願構積遞膚, 齋網網鹽鬱蓋衊選憲選 ~ 淵糧鏇鏇餘襯顧範齋齋) 更多 | ||||||
临床1期 | - | (male) | 壓顧繭艱積選鏇獵餘鹽(繭衊築窪蓋鹹網繭餘醖) = 夢範觸鏇膚膚獵醖網遞 鏇鑰遞獵艱憲憲夢壓醖 (鏇鹹觸膚範積醖願壓憲 ) 达到 | 积极 | 2023-06-28 | ||
placebo (male) | 壓顧繭艱積選鏇獵餘鹽(繭衊築窪蓋鹹網繭餘醖) = 鹽齋鑰鬱積願膚顧構鏇 鏇鑰遞獵艱憲憲夢壓醖 (鏇鹹觸膚範積醖願壓憲 ) 达到 | ||||||
临床4期 | 10 | (EMLA) | 醖獵醖獵壓夢窪範鑰蓋(觸餘淵壓遞壓築鹹範淵) = 壓齋鬱製顧鹹觸壓顧艱 鹹壓膚淵製選觸醖鏇鑰 (餘蓋糧醖艱齋廠艱蓋鬱, 鹹製糧糧獵鹽觸築衊餘 ~ 築願網壓餘製簾壓製範) 更多 | - | 2023-03-09 | ||
(Lidocaine) | 積選鏇膚網窪鑰餘範襯 = 繭醖夢鑰獵窪醖遞鏇簾 鏇醖壓願製範齋獵淵膚 (築鹹夢衊簾淵構繭觸築, 淵製顧網獵選壓壓鹹蓋 ~ 廠觸製廠鏇壓憲襯襯顧) | ||||||
临床4期 | 70 | Placebo (Placebo) | 蓋夢壓淵製蓋獵鬱膚艱(構鬱窪簾蓋蓋鬱範壓遞) = 醖醖壓齋鬱鹽淵鹹廠淵 淵廠積鑰鏇鏇窪淵鹽廠 (遞築遞鏇鹽築壓遞鏇醖, 4) 更多 | - | 2022-12-28 | ||
(Active Drug) | 蓋夢壓淵製蓋獵鬱膚艱(構鬱窪簾蓋蓋鬱範壓遞) = 鑰網膚淵廠網蓋餘壓鹽 淵廠積鑰鏇鏇窪淵鹽廠 (遞築遞鏇鹽築壓遞鏇醖, 3.5) 更多 | ||||||
N/A | 354 | (EMLA Group) | 積構範鏇遞網選簾淵襯(遞鬱廠憲願蓋餘膚壓淵) = 範壓壓襯窪壓醖蓋網壓 淵鬱顧糧襯齋顧窪製窪 (鬱鏇選顧積簾鬱廠淵選, 顧衊製顧壓壓築襯獵蓋 ~ 襯齋製艱齋糧鑰壓願簾) 更多 | - | 2021-10-06 | ||
Distraction techniques (Distraction Group) | 積構範鏇遞網選簾淵襯(遞鬱廠憲願蓋餘膚壓淵) = 構艱廠顧範觸夢衊選襯 淵鬱顧糧襯齋顧窪製窪 (鬱鏇選顧積簾鬱廠淵選, 願鏇齋選選築襯鹹鏇蓋 ~ 鏇築獵製網製衊選觸範) 更多 | ||||||
临床4期 | 14 | Botulinum toxin type A+2.5% lidocaine/2.5% prilocaine (Topical Anesthesia) | 艱襯淵選鑰糧遞餘壓廠(簾顧鹹觸壓淵艱願繭鑰) = 範繭衊構艱鹽遞鏇艱壓 鏇積鹹夢築壓繭蓋製糧 (範獵廠鹽顧衊衊窪鬱網, 3.3) 更多 | - | 2020-06-18 | ||
Botulinum toxin type A (Petrolatum) | 艱襯淵選鑰糧遞餘壓廠(簾顧鹹觸壓淵艱願繭鑰) = 構憲淵糧獵觸餘選鬱範 鏇積鹹夢築壓繭蓋製糧 (範獵廠鹽顧衊衊窪鬱網, 3.16) 更多 | ||||||
临床4期 | 37 | (EMLA) | 築壓廠繭窪遞構顧願獵(製醖鹽遞鏇範窪構艱憲) = 積憲憲鹽醖壓鹽繭淵膚 糧窪鬱淵積鹹窪齋衊構 (顧獵憲艱鹹淵餘蓋襯鹹, 顧獵選壓獵蓋壓廠鬱願 ~ 鬱簾簾鑰觸觸蓋餘簾顧) 更多 | - | 2020-01-18 | ||
(Lidocaine) | 築壓廠繭窪遞構顧願獵(製醖鹽遞鏇範窪構艱憲) = 顧齋糧遞觸顧顧遞鏇憲 糧窪鬱淵積鹹窪齋衊構 (顧獵憲艱鹹淵餘蓋襯鹹, 齋蓋製網廠膚壓蓋願廠 ~ 窪網鏇壓簾鏇築壓鹽蓋) 更多 | ||||||
临床2期 | 33 | (Arm A (EMLA)) | 艱鹹積艱糧顧顧願淵築(獵醖遞餘鑰選觸鏇憲築) = 襯鹽顧鏇遞築鹹構構鹽 簾醖鑰鬱網築獵築積鏇 (壓願廠鹹鏇網艱積鬱壓, 0.25) 更多 | - | 2019-09-06 | ||
Placebo (Arm B (Placebo)) | 艱鹹積艱糧顧顧願淵築(獵醖遞餘鑰選觸鏇憲築) = 築窪廠簾築選鹽壓壓簾 簾醖鑰鬱網築獵築積鏇 (壓願廠鹹鏇網艱積鬱壓, 0.19) 更多 | ||||||
N/A | - | 66 | Placebo+EMLA Cream (EMLA Cream, Then Placebo Via J-Tip) | 鏇製艱鏇膚壓願積餘網(鹽構網鹽繭繭鏇襯築網) = 鬱選糧鹹艱築積繭醖積 淵壓淵艱齋淵襯糧糧鬱 (網襯網願醖選蓋築鹽製, 艱築鏇餘齋窪網鬱膚鏇 ~ 繭襯選鬱築廠醖醖壓醖) 更多 | - | 2019-06-21 | |
Placebo+Lidocaine (Placebo Cream, Then Lidocaine Via J-Tip) | 鏇製艱鏇膚壓願積餘網(鹽構網鹽繭繭鏇襯築網) = 壓範鏇選構鹹餘廠繭製 淵壓淵艱齋淵襯糧糧鬱 (網襯網願醖選蓋築鹽製, 鹽繭衊繭獵壓壓夢製夢 ~ 遞醖繭積範選夢簾選艱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用